Gilead has plunked down (what is, for it) a very good sized bet — to extend a foray into immuno-oncology, and in part diversify itself from being a pure HIV therapies, and mRNA-approach R&D vaccines-candidate house. It will still make scads of shekels in that wheel-house, but now looks beyond 2032. Very forward-thinking, indeed.
Here’s the latest, from a London based outlet:
…Gilead Sciences is buying autoimmune disease biotech Ouro Medicines for nearly $2.2bn as the drugmaker kick-starts a dealmaking spree emboldened by its near-record share price.
The California-based company will pay privately held Ouro’s investors just less than $1.7bn in cash when the deal closes and a further $500mn once certain clinical trial milestones are hit, Gilead said on Monday after the FT reported a deal was imminent.
The transaction is Gilead’s second biotech acquisition in the past month following its $7.8bn takeover of Arcellx, with which it had an existing partnership to develop a novel cell therapy for patients with … multiple myeloma….
Okay — that’s two in the power alley, in a single morning. May be done for the day. Heh. Onward.
नमस्ते
Powerline Lies... 